WASHINGTON, Jan 18 (Reuters) - A U.S. regulatory review of a bowel drug from Adolor Corp (ADLR.O: Quote, Profile, Research) and GlaxoSmithKline (GSK.L: Quote, Profile, Research) (GSK.N: Quote, Profile, Research) found a heart attack rate similar to that of a placebo, but the investigators said no conclusion could be drawn because of limited patient follow-up.
